Liver test abnormalities in patients with HIV mono-infection : assessment with simple non-invasive fibrosis markers by R. Lombardi et al.
© 2017 Hellenic Society of Gastroenterology www.annalsgastro.gr
Annals of Gastroenterology (2017) 30, 349-356O R I G I N A L  A R T I C L E
Liver test abnormalities in patients with HIV mono-infection: 
assessment with simple noninvasive fibrosis markers
Rosa Lombardia, Robert Leverb, Colette Smithc, Neal Marshallb, Alison Rodgerc, Sanjay Bhaganib, 
Emmanuel Tsochatzisa
Royal Free Hospital and UCL, London, UK
Abstract Background Patients with HIV mono-infection may develop chronic liver disease due to a number 
of factors including hepatic steatosis. We estimated the prevalence and predictors of hepatic steatosis 
and fibrosis in a cohort of HIV-mono-infected patients with persistently deranged liver function tests.
Methods Of 2398 consecutive patients at one UK clinical center, 156  (6.5%) had persistently 
abnormal transaminases in at least two measurements six months apart. We used APRI and FIB4 
scores to determine the presence of significant and/or advanced fibrosis in this group as well as its 
potential associations.
Results Mean age was 47.5±8.5  years and 91% (142/156) were males. Diabetes mellitus was 
present in 11% of patients; hypertension in 18%; and dyslipidemia in 52%. Almost all were on 
antiretroviral therapy (ART) (97%) and most were virologically suppressed (94%). Steatosis was 
detected by ultrasound in 71% of patients. The prevalence of FIB4≤1.45, 1.46-3.24 and >3.25 
was 67%, 29% and 4%, respectively, and that of APRI≤0.5, 0.51-1.49 and >1.5 was 52%, 45% and 
3% respectively. In multivariate analysis, only cumulative ART exposure was associated with 
FIB4>1.45 (odds ratio [OR] 1.008, 95% confidence interval [CI] 1.000-1.016), while APRI>0.5 was 
associated with higher alanine aminotransferase levels (OR 1.033, 95%CI 1.015-1.510). Twenty 
patients had a liver biopsy, of whom 13 had non-alcoholic fatty liver disease (NAFLD).
Conclusions Elevated transaminases are often present in HIV-mono-infected patients and this 
may be associated with NAFLD and/or ART. Non-invasive screening for the presence of NAFLD 
and fibrosis in all HIV-mono-infected patients as part of their routine clinical management should 
be further explored.
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Introduction
In the era of effective antiretroviral therapy (ART), chronic 
liver disease is an important cause of morbidity and mortality 
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among HIV-positive individuals, even in the absence of 
hepatitis C (HCV) and B (HBV) co-infections [1,2]. Mild 
elevation of transaminases in HIV-positive individuals on 
ART is frequently reported [3], although the etiology is 
often indeterminate. In a study by Crum-Cianflone, elevated 
transaminases were found in 80  (27%) of 299 HIV-mono-
infected patients on ART and steatosis was detected on 
ultrasound (US) in 30%, though in 51% the cause of liver 
dysfunction remained unexplained [4].
Fatty liver due to metabolic syndrome and/or ART exposure 
is an increasingly recognized cause of liver test abnormality 
in HIV-mono-infected patients [3]. Non-alcoholic fatty liver 
disease (NAFLD) is the hepatic manifestation of metabolic 
syndrome [5], but could also represent a long-term toxicity of 
ART as nucleoside reverse-transcriptase inhibitors (NRTIs) and 
to a lesser extent protease inhibitors (PIs), are associated with 
insulin resistance and mitochondrial toxicity [6]. Moreover, 
specific HIV-related factors, such as lipodystrophy or the HIV 
virus per se, may predispose to NAFLD [7,8]. NAFLD has a 
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prevalence of 20% in the general population of industrialized 
countries, which rises to more than 50% among those with 
HIV infection [9,10].
Since NAFLD encompasses a wide spectrum of disease, 
ranging from simple steatosis to non-alcoholic steatohepatitis 
(NASH), fibrosis and eventually cirrhosis [11], the early 
detection of liver fibrosis prior to the onset of complications 
associated with decompensated liver disease is crucial. 
Noninvasive fibrosis tests are increasingly used for the 
assessment of fibrosis in patients with liver disease [12], 
including those who are HIV positive [13].
In this study, we retrospectively evaluated the prevalence 
and predictors of liver fibrosis in a cohort of HIV-mono-
infected patients with persistently elevated transaminases, 
using simple serum noninvasive fibrosis panels, namely the 
FIB4 and APRI scores. In addition, we assessed the presence of 
hepatic steatosis and associated features in this cohort.
Patients and methods
Study population
This was a retrospective cross-sectional audit of consecutive 
HIV-mono-infected patients who attended the HIV dedicated 
outpatient service at Royal Free Hospital, London, UK, 
between January and December 2014. A  clinical database 
was used to identify patients with persistently elevated 
transaminases in at least two measurements six months apart. 
Serum levels more than 39 IU/L and 41 IU/L were considered 
as abnormal for aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT), respectively. Patients with evidence 
of HCV or HBV co-infection, as well as other documented 
causes of liver disease other than NAFLD were excluded. 
Further information for patients with persistently abnormal 
transaminases was retrieved from their clinical notes.
Laboratory investigations and epidemiological and clinical 
features were retrieved from the clinical database for all 
included patients. The presence of diabetes, hypertension and 
dyslipidemia was documented, as well as relevant medications.
HIV specific information was also obtained; this included 
time since diagnosis, duration of ART, most recent CD4+ 
count (n/mm3) and HIV viral load (RNA copies/mm3). HIV 
RNA copies <40/mL defined virologic suppression.
Liver fibrosis and steatosis assessment
We obtained the results of abdominal US scans and transient 
elastography (TE) with FibroScan®, which were performed 
as part of routine clinical care, to further investigate the liver 
test abnormalities and stage of fibrosis, respectively. US and 
TE findings were included if within 6  months of the date of 
transaminase measurement.
The presence of significant (≥F2 METAVIR stage) or 
advanced (≥F3 METAVIR stage) liver fibrosis was evaluated by 
APRI and FIB4 scores, respectively. APRI consists of AST and 
platelet count in the formula:
APRI = [AST levels (IU/L)/AST upper limit of normal 
(ULN) (IU/L)/Platelets (109/L)] × 100
It has dual cutoffs for ruling out (<0.5) or diagnosing (>1.5) 
significant fibrosis [14]. FIB4 consists of age, AST, ALT and 
platelet count in the formula:
FIB4 = [Age (years) ×  AST  (IU/L)]/[Platelets (109/L) × 
ALT (IU/L)]
It also has dual cutoffs for ruling out (<1.45) or diagnosing 
(>3.25) advanced fibrosis [15]. These tests usually have dual 
cutoffs: a high cutoff with high specificity and a low cutoff with 
high sensitivity. Depending on the clinical scenario and the 
disease prevalence, the low or high cutoff is used at the expense 
of increased false positives and false negatives respectively. If 
these cutoffs are combined, then the false positives and false 
negatives are minimized; however, a number of patients will 
fall in the indeterminate range of fibrosis (i.e., their score will 
be indeterminate, between the low and the high cutoff) and 
they will need either further noninvasive testing or a liver 
biopsy [16].
In a small subgroup of 19 patients, TE was performed with 
a FibroScan® system (Echosens; Paris, France), after at least 
6 hours of fasting. Results in kilopascals (kPa) were calculated 
as the mean of ten valid measurements, obtained by placing 
the probe on the patient’s skin between the ribs at the level of 
the right lobe of the liver in a dorsal decubitus position. Only 
determinations of liver stiffness with an interquartile range 
for measurements within 30% and a ratio of success rate of 
measurements (number of total measurements/number of 
valid acquisition) >60% were considered reliable. Liver stiffness 
values >7.4 kPa were considered suggestive of significant 
fibrosis.
Finally, 20  patients in the same cohort had previous 
liver biopsies as part of their routine clinical care. The 
presence and severity of steatosis, as well as the histological 
grading  and  staging were assessed according to the Brunt 
score [17].
Statistical analysis
All data were analyzed using the statistical package SPSS 
(version  22.0, IBM, New  York, NY, USA). Statistical analysis 
was performed using t-test, ANOVA, Mann-Whitney test or 
Kruskal-Wallis test for comparisons of continuous variables 
between or among groups, the corrected chi-square method 
or two-tailed Fisher’s exact test was used for comparisons of 
qualitative data, and Spearman’s coefficient for correlations of 
quantitative data, when appropriate. Multivariate analysis was 
performed using logistic regression models to assess predictors 
of steatosis and fibrosis with APRI and FIB-4 values of >0.5 
and >1.45 respectively. Only variables with a P-value ≤0.10 in 
the univariate analysis were entered in the multivariate analysis 
models. A two-tailed P-value <0.05 was considered to indicate 
a statistically significant difference between groups.
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Results
Baseline characteristics
Of 2398 consecutive patients with HIV mono-infection 
who were evaluated between January and December 2014, 
156 (6.5%) had persistently elevated transaminases in at least 
two measurements six months apart and were included in the 
analysis. The mean age of those included was 47.5 years and 91% 
were male. Clinical, biochemical and virological characteristics 
are reported in Table  1. In particular, 28  patients (17.9%) 
had hypertension, 17  (10.9%) had diabetes and 80  (51.9%) 
had hyperlipidemia, while 47 (30.5%) were on lipid-lowering 
medication.
AST and ALT values <2  times ULN were found in 93.6% 
and 81.4% of patients, respectively, 2-3 times ULN in at least 
one measurement in 3.8% and 14.1%, and >3 times ULN in at 
least one measurement in 2.6% and 4.5% of the cohort.
Almost all patients were on ART (n=154, 97%), with a 
median length of treatment of 11  years (interquartile range 
[IQR] 0-26  years), and the majority of them had virological 
suppression (n=146, 93.6%). Mean time since diagnosis 
was 14  years (IQR 2-30  years). CD4 counts <200/mm3 were 
present only in 3  (1.9%) patients and median viral load was 
39 copies/mm3 (IQR 39-2622).
Information about the specific treatment regimen was 
available for only 97 patients. The most common drugs used 
were NRTIs in 86  (88.7%) of treated patients, while PIs and 
non-NRTIs were prescribed in 41 (42.3%) and 46 (47.4%) of 
patients, respectively.
Prevalence and predictors of hepatic steatosis
US examination was performed in 66  (42.3%) patients and 
fatty liver was detected in the majority of these (n=47, 71.2%), 
as shown in Table  2. Nevertheless, no association was found 
between the presence of US steatosis and patients’ clinical features, 
as shown in Table  3. In particular, there was no association 
between the presence of steatosis and metabolic features, namely 
hypertension, diabetes and dyslipidemia. Importantly, fatty liver 
was not significantly associated with the time since diagnosis, 
the length of ART, or the category of antiviral drugs used. On 
univariate analysis, fenofibrate use was significantly associated 
with the absence of steatosis on US (P=0.022), but this association 
was lost in the multivariate model.
Prevalence and predictors of significant and advanced 
liver fibrosis
Considering the high cutoff of >1.5 for APRI, we categorized 
5 (3.2%) patients as having significant fibrosis (≥F2), whereas 
values <0.5 excluded this diagnosis in 51.9% of them. On the 
other hand, FIB4>3.25 suggested advanced fibrosis (≥F3) 
in 6  (3.8%) patients, while values ≤1.45 (<F3) were found in 
Table 1 Characteristics of the cohort of HIV-mono-infected patients 
with deranged transaminases
Characteristics N=156
Male sex (%) 143 (91.7)
Age, years 47.5±8.5
AST, IU/L 41 (22-299)
ALT, IU/L 56 (29-372)
GGT, U/L 74 (13-960)
ALP, U/L 86±34
PLT, /mm3 217±5
Diabetes, n (%) 17 (11)
Hypertension, n (%) 28 (18.2)
Dyslipidemia, n (%) 81 (51.9)
Currently receiving statin, n (%) 47 (30.5)
Currently receiving fenofibrate, n (%) 7 (4.5)
Time since diagnosis, years 14 (2-30)
Current treatment, n (%) 154 (97)
PIs*, n (%) 41 (42.3)
NRTIs*, n (%) 86 (88.7)
NNRTs*, n (%) 40 (41.2)
Duration of ART years (amongst those 
currently exposed)
11 (0-26)
HIV-RNA, copies/mm3 >100,000 0
Virologic suppression 146 (93.6)
CD4+, cells/mm3 683 (4-1900)
Data expressed as mean±SD for quantitative variables with normal 
distribution; data expressed as median (interquartile range) for quantitative 
variables without normal distribution, *Information on drug category 
available only in 97 patients (62%)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
GGT, γ-glutamyltranspeptidase; ALP, alkaline phosphatase; PLT, platelets; 
PIs, protease inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; 
NNRTIs, non-nucleoside reverse transcriptase inhibitors
Table 2 Prevalence of liver disease in cohort of HIV-mono-infected 
patients with deranged transaminases
Variables N=156
Ultrasound examinations, n (%) 66 (42.3)
Ultrasound steatosis, n (%) 47 (71.2)
FIB4 score
1.45, n (%) 105 (67.3)
1.46-3.24, n (%) 45 (28.8)
≥3.25, n (%) 6 (3.8)
APRI index
0.5, n (%) 81 (51.9)
0.51-1.49, n (%) 70 (44.9)
≥1.5, n (%) 5 (3.2)
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67.3% of the cohort. Forty-five (28.8%) and 70 (44.9%) patients 
fell into the “indeterminate” diagnostic zone of FIB4 and APRI, 
respectively, as shown in Table 2.
For further analysis, and in keeping with the use of 
noninvasive tests for screening, we considered a threshold of 
1.45 for FIB4 and of 0.5 of APRI to rule out the presence of 
advanced or significant fibrosis, respectively, in our cohort 
of HIV-mono-infected patients.
In univariate analysis, FIB4 >1.45 (n=51, 32.7%), was 
significantly associated with both time since HIV diagnosis 
(14±7 vs. 16±6 years, P=0.019) and duration of ART (10±6 vs. 
13±6 years, P=0.002). Moreover, diabetes was significantly more 
prevalent in patients with a FIB4 score >1.45 compared to those 
with values <1.45 (17.6% vs. 7.6%, P=0.098). Nevertheless, in 
the multivariate analysis, only duration of ART maintained this 
association (OR 1.008, 95%CI 1.000-1.016; P=0.04) (Table 4).
On the other hand, APRI values >0.5 were found in 75 (48%) 
patients and only ALT levels were significantly increased in 
patients with evidence of significant fibrosis (78±49 vs. 56±13; 
OR 1.033, 95%CI 1.015-1.510, P=0.01). In contrast to FIB4, 
neither the time since HIV diagnosis nor the use of ART or 
the presence of diabetes was associated with an increased 
APRI score. As with FIB4, no association with demographic or 
metabolic features was noted (Table 5). Interestingly, no relation 
was found between the presence of liver fibrosis assessed by 
both FIB4 and APRI scores and evidence of steatosis on US.
A small subset of patients also underwent TE (n=19, 12.1%) 
and a liver biopsy (n=20, 12.8%). Considering a threshold 
stiffness value of 7.4 kPa, 4 (21.1%) patients were classified as 
having significant fibrosis, while stiffness values more than 10 
kPa were found in only 1 patient, suggesting more advanced 
liver disease.
Despite the small number of liver biopsies, histology 
showed NAFLD in 13 (65%) patients, one of whom was also 
diagnosed with cirrhosis. Moreover, features of drug reaction 
were present in 2  cases, while 4  patients had non-specific 
histological changes and 1 biopsy was normal.
Discussion
In this study, we demonstrated that persistently abnormal 
transaminases are fairly prevalent in unselected HIV-mono-
Table 3 Variables associated with the presence of US liver steatosis in the cohort of HIV-mono-infected patients
Patient characteristics No steatosis (N=19) Steatosis (N=47) Univariate analysis
P-value
Multivariate analysis
P-value OR (95%CI)
Age, years 46.9±9.5 47.9±8.5 0.700
Male sex (%) 16 (84.2) 43 (91.5) 0.401
Diabetes mellitus, n (%) 0 (0) 6 (12.8) 0.171
Hypertension, n (%) 5 (26.3) 9 (19.4) 0.529
Dyslipidemia, n (%) 11 (57.9) 25 (53.2) 0.790
Statin, n (%) 7 (36.8) 15 (31.9) 0.779
Fenofibrate, n (%) 3 (15.8) 0 (0) 0.022 NS
PLT, ×103/mm3 218±51 220±52 0.836
AST, IU/L 46±14 46±22 0.466
ALT, IU/L 61±15 66±28 0.832
ALP, U/L 92±37 91±29 0.835
GGT, U/L 194±273 97±86 0.428
Duration since diagnosis, years 15±8 14±7 0.451
Duration of treatment, years 12±6 16±6 0.729
PIs, n (%) 4 (21) 13(27.7) 1.000
NRTIs, n (%) 11 (57.9) 32 (68.1) 1.000
NNRTs, n (%) 6 (31.6) 14 (29.8) 0.737
Virologic suppression, n (%) 18 (94.7) 44 (93.6) 1.000
CD4+ <200/mm3, n (%) 0 0 -
FIB4 >1.45, n (%) 7 (36.8) 17 (36.2) 1.000
APRI >0.5, n (%) 10 (52.6) 25 (53.2) 1.000
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltranspeptidase; ALP, alkaline phosphatase; PLT, platelets; PIs, protease inhibitors; 
NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; US, ultrasound; OR, odds ratio; 95%CI, 95% confidence 
interval
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infected patients (156/2398, 6.5%). More importantly, 4% of 
these patients had evidence of advanced fibrosis based on simple 
noninvasive fibrosis tests. Despite the presence of persistently 
deranged liver function tests (LFTs) in this group, there was 
inconsistent further investigation of these abnormalities; just 
66 (42%) patients had undergone a US examination and only 
19 (12%) had a TE, despite the noninvasiveness and relatively 
low cost of these techniques.
A rise in liver enzymes in HIV-mono-infected individuals 
on ART has been previously reported. A cross-sectional study 
by Sterling et al reported elevated transaminases in 20% of 
679  patients and a positive association with high viral load 
and features of metabolic syndrome [18]. Maida et al studied 
a cohort of 3200 individuals with a long history of HIV 
infection and ART exposure and found abnormal LFTs in only 
17  (0.5%) patients, of whom 10  (58.8%) had histologically 
advanced fibrosis (F3-F4) and clinically advanced liver disease. 
However, in this study harmful alcohol use and medications 
predisposing to steatosis were excluded [19]. On the other 
hand, in a prospective study of 2365 HIV-mono-infected 
individuals who were followed for a 5-year period, 385 (16%) 
developed persistent ALT elevation, which was associated with 
increased body mass index, high HIV viral load and exposure 
to NRTIs, in particular zidovudine and stavudine [20].
The underlying etiology of increased LFTs in people who 
are HIV positive often remains unrecognized, as liver biopsy 
is not routinely performed. Nevertheless, many studies have 
indicated that NAFLD is more prevalent in this category of 
patients, potentially progressing to NASH and liver fibrosis.
A histological evaluation of a cohort of 20 HIV-mono-
infected individuals with chronically increased LFTs 
demonstrated the presence of steatosis in 18 (60%) patients, of 
whom 16 (88.9%) had NASH and 13 (72.2%) had fibrosis [21]. 
Morse et al biopsied a cohort of 62  patients with similar 
features and found steatosis in 45  (73%), NASH in 34  (55%) 
and bridging fibrosis in 11 (17%) patients [22].
These data are similar to those of our study and indicate 
the necessity of screening HIV positive individuals for the 
presence of steatosis and fibrosis, especially when LFTs are 
deranged. In fact, in the subgroup of patients who underwent 
a liver US, NAFLD was present in the majority (47/66, 71.2%). 
Moreover, even though a liver biopsy was performed in only in 
20 patients, histology showed NAFLD in 13 (65%), and NASH 
in 5 (25%) patients, of whom one had cirrhosis.
The prevalence of steatosis is likely to be even higher than 
70%, as US can detect steatosis only when more than 20-30% 
of hepatocytes are involved. Importantly, in our study there 
was no significant association with metabolic, anthropometric 
Table 4 Variables associated with the presence of liver fibrosis assessed by FIB4 in the whole cohort of HIV-mono-infected patients
Patient characteristics FIB4 ≤1.45 (N=105) FIB4 >1.46 (N=51) Univariate analysis
P-value
Multivariate analysis
P-value OR (95%CI)
Age, years - - -
Male sex (%) 94 (89.5) 49 (96.1) 0.224
Diabetes mellitus, n (%) 8 (7.6) 9 (17.6) 0.098 NS
Hypertension, n (%) 16 (15.2) 12 (23.5) 0.268
Dyslipidemia, n (%) 58 (55.2) 23 (45.1) 0.305
Statins, n (%) 32 (30.5) 15 (29.4) 1.000
Fenofibrate, n (%) 5 (4.8) 2 (4) 1.000
PLT, ×103/mm3 - - -
ALT, IU/L - - -
AST, IU/L - - -
ALP, U/L 88±33 80±31 0.138
GGT, U/L 99±123 156±191 0.104
Time since HIV diagnosis, years 14±7 16±6 0.019 NS
Duration of ART, years 10±6 13±6 0.002 0.041 1.008 (1.000-1.016)
PIs, n (%) 23 (21.9) 18 (35.3) 0.202
NRTIs, n (%) 55 (52.4) 31 (60.8) 1
NNRTs, n (%) 28 (26.7) 12 (23.5) 0.391
Virologic suppression, n (%) 98 (9.3) 48 (94.1) 1.000
CD4+ <200/mm3, n (%) 1 (0.9) 2 (3.9) 0.249
US steatosis, n (%) 30 (28.6) 17(33.3) 1
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltranspeptidase; ALP, alkaline phosphatase; PLT, platelets; PIs, protease inhibitors; 
NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; US, ultrasound; OR, odds ratio; 95%CI, 95% confidence 
interval
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and either infection- or ART-related features. However, as US 
reports were available for less than half of our cohort, this likely 
reflects under-powering of the study to detect any significant 
associations.
Conversely, two other studies reported a lower prevalence 
of NAFLD assessed by imaging techniques. Guaraldi et al 
detected steatosis by CT scan in 37% of 225 HIV-mono-
infected patients, and found an association with cumulative 
NRTI exposure (OR 1.12, 95%CI 1.03-1.22; P=<0.001) and 
obesity (OR 1.07, 95%CI 1.03-1.11; P<0.001) [23]. In contrast, 
in another study, though steatosis was present on US in 31% 
and by histology in 33% of 216 HIV-mono-infected patients, 
there was no association with either duration of HIV infection 
or ART, as only obesity (OR 2.1, 95%CI 1.6-2.8; P<0.001) and 
hypertriglyceridemia (OR 1.2, 95%CI 1-1.5; P=0.03) reached 
statistical significance [24]. Nevertheless, in both studies less 
than 30% of patients had deranged LFTs; this could possibly 
explain the lower prevalence of steatosis compared to our 
findings.
Using the APRI and FIB4 scores, we classified 5 (3.2%) and 
6 (3.8%) patients as potentially having significant and advanced 
fibrosis, respectively. Although TE appears to be the best 
noninvasive tool in HIV infected patients, showing excellent 
accuracy for the detection of liver cirrhosis and moderate 
accuracy for significant fibrosis [25,26], it was available in only 
a small subset of the cohort, where it suggested significant 
fibrosis in 4  patients. On the other hand, our data suggest 
that 81  (51.2%) and 105  (67.3%) patients could be excluded 
from having significant and advanced fibrosis according to 
APRI and FIB4, respectively. Indeed, APRI and FIB4 have a 
higher diagnostic accuracy in ruling out rather than ruling 
in the presence of significant/advanced fibrosis and are ideal 
screening tests, as they have a negative predictive value of 
>90% [15,27]. Low FIB4 scores are associated with excellent 
liver-related outcomes in patients with NAFLD over a 10-year 
period of follow up; therefore, these scores can be used in the 
HIV mono-infection setting [28].
The low prevalence of significant and advanced fibrosis 
based on simple noninvasive tests is compatible with previously 
published data. In a cohort of 818 HIV positive women, the 
majority of patients (86.6%) had FIB-4 values ≤1.45, while 
increasing FIB4 values were associated with higher HIV viral 
load [29]. Similarly, in a cohort of 225 HIV-mono-infected 
patients, 28 were classified as not having fibrosis on FIB-4 [23], 
while in another cohort of 62 patients FIB4 ≤1.45 and >3.25 
were found in 37 (59.7%) and 5 (8%) patients, respectively [22]. 
Table 5 Variables associated with the presence of liver fibrosis assessed by APRI index in the whole cohort of HIV-mono-infected patients
Patient characteristics APRI ≤0.5 (N=81) APRI>0.51 (N=75) Univariate analysis
P-value
Multivariate analysis
P-value OR (95%CI)
Age, years 47.1±8.3 47.9±8.8 0.57
Male sex (%) 73 (89.5) 70 (96.1) 0.568
Diabetes mellitus, n (%) 9 (7.6) 8 (17.6) 1
Hypertension, n (%) 14 (15.2) 14 (23.5) 0.836
Dyslipidemia, n (%) 45 (55.2) 36 (45.1) 0.423
PLT, ×103/mm3 - - -
Statin, n (%) 23 (30.5) 24 (29.4) 0.601
Fenofibrate, n (%) 4 (4.9) 3 (4) 1.000
ALT, IU/L 56±13 78±49 0.001 0.01 1.033 (1.015-1.510)
AST, IU/L - - -
ALP, U/L 87±28 85±37 0.751
GGT, U/L 85±64 153±201 0.223
Duration of infection, years 15±7 14±7 0.425
Duration of treatment, years 11±6 11±6 0.767
PIs, n (%) 19 (23.4) 22 (29.3) 0.311
NRTIs, n (%) 45 (55.5) 41 (54.7) 1.000
NNRTs, n (%) 20 (24.7) 20 (26.7) 0.685
CD4+ <200/mm3, n (%) 1 (0.9) 2 (3.9) 0.608
Virologic suppression, n (%) 76 (93.8) 70 (93.3) 1.000
US steatosis, n (%) 22 (28.6) 25 (33.3) 1.000
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltranspeptidase; ALP, alkaline phosphatase; PLT, platelets; PIs, protease inhibitors; 
NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; US, ultrasound; OR, odds ratio; 95%CI, 95% confidence 
interval 
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Conversely, a slightly higher prevalence of 8% of APRI values 
>1.5 was found in 432 HIV-mono-infected patients, and both 
diabetes and detectable HIV viremia were confirmed as risk 
factors for significant fibrosis [30]. However, the presence of 
obesity in 50% of the cohort could have contributed to the 
higher prevalence of significant fibrosis.
In our study, the duration of ART was the only factor 
independently associated with the presence of fibrosis based on 
FIB-4. The impact of ART on liver fibrosis is controversial, as 
highlighted by conflicting reports on worsening with long-term 
use of ART, especially didanosine or stavudine [9,31], absence 
of significant effect [22], or even improvement following 
commencement of PIs [32,33]. Furthermore, Mendeni et al 
followed a cohort of 1112 HIV-mono-infected patients for 
approximately 6 years and found that progression of fibrosis, 
assessed by APRI and FIB4, was prevented by viral control with 
early ART, provided that didanosine use was avoided [33].
Interestingly, in this study neither FIB4 nor APRI showed 
any association with metabolic features or increasing age. 
Diabetes was significantly associated with increased FIB4 
values, but only in the univariate analysis. These data reflect 
the characteristics of our population, as the HIV patients were 
relatively young (mean age 47  years) and both diabetes and 
hypertension had a low prevalence, thus limiting the power of 
this study to detect any associations with fibrosis.
This study has limitations. First, it was a cross-sectional 
study, so it was not possible to define the dynamic process 
underlying the development of both steatosis and fibrosis in 
HIV positive patients. Therefore, these data should be assessed 
prospectively, in order to evaluate the true prognostic impact 
of hepatic steatosis and fibrosis in HIV. Second, the selection of 
patients on the basis of elevated transaminases could have led 
to an underestimation of fatty liver disease, given their lack of 
sensitivity in diagnosing NAFLD or NASH [34]. Third, detection 
of steatosis by US could also have underestimated the prevalence 
of NAFLD, as the accuracy of this technique is suboptimal. In 
addition, an element of undisclosed alcohol abuse could also 
have contributed to the high steatosis prevalence in this cohort.
In conclusion, the presence of liver disease is under-
investigated in HIV-mono-infected patients, despite deranged 
LFTs. Such abnormalities are often associated with the presence 
of NAFLD, and could potentially evolve into progressive liver 
fibrosis. A  potential role for ART in this scenario has yet to 
be determined, but it is likely that NAFLD could represent 
a long-term toxicity of antiviral therapy, as suggested by the 
association of the length of antiviral treatment and liver fibrosis 
and evidence from other studies. A wide range of noninvasive 
tools for the assessment of liver fibrosis are currently available; 
therefore, noninvasive screening for the presence of NAFLD 
and fibrosis should be a part of the routine clinical management 
of HIV-mono-infected patients receiving antiretroviral 
treatment. Moreover, aggressive treatment of the metabolic 
syndrome components should be undertaken in HIV positive 
patients with steatosis, given the well-established association 
of NAFLD with increased cardiovascular morbidity and 
mortality [35].
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